Black Diamond Therapeutics Appoints Mark Velleca, Current Chairman As Chief Executive Officer Effective Immediately Succeeding The Company's Ceo And Co-founder, David Epstein, Who Has Stepped Down And Will Continue To Serve As A Board Member
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics has appointed its current Chairman, Mark Velleca, as the new CEO, effective immediately. He succeeds the company's CEO and co-founder, David Epstein, who has stepped down but will continue to serve as a board member.
September 18, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Black Diamond Therapeutics' CEO and co-founder, David Epstein, has stepped down and is succeeded by current Chairman, Mark Velleca. Epstein will continue to serve on the board.
Leadership changes can cause uncertainty and impact a company's stock price. However, as the new CEO is an internal appointment and the outgoing CEO will remain on the board, the impact is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100